CaroGen unveils research for hepatitis B therapeutic vaccine technology
An estimated 240 million people around the world suffer from chronic hepatitis B virus infections. Approximately 600,000 people die from these infections every year.
The article is titled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.” It was published online in the August issue of the Journal of Virology.
“The publication of this work is a major milestone for CaroGen, as it provides a peer-reviewed report of our proof-of-concept HBV vaccine studies to date,” Dr. Bijan Almassian, CEO of CaroGen, said.
The research was conducted at Yale University by Dr. John Rose and Dr. Michael Robek. They used their virus-like vesicle (VLV) platform technology, which was developed by Dr. John Rose, who is a virologist at Yale University and a professor of pathology at the Yale School of Medicine. The technology receive licensure from CaroGen in 2012.
“There is a clear need for new therapies for chronically infected individuals,” Dr. Michael Robek, senior author of the research and faculty member in the department of pathology at Yale University, said. “With the virus-like vesicle technology and hepatitis B vaccine candidates under development, we are looking to deliver the needed balance of safety combined with induction of functional immune responses.”